Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment-Reference-Cited by-同舟云学术

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment

Published:2004-01 Issue:1 Volume:40 Page:33-42
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Linderholm B.,Andersson J.,Lindh B.,Beckman L.,Erlanson M.,Edin K.,Tavelin B.,Grankvist K.,Henriksson R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor;Schlessinger;Cell,2002

2. Evaluation of the united states food and drug administration-approved scoring and test system of her-2 protein expression in breast cancer;Birner;Clin. Cancer Res.,2001

3. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer;Pauletti;J. Clin. Oncol.,2000

4. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer [see comments];Paik;J. Natl. Cancer Inst.,1998

5. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer;Harris;Cancer,1994

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105);Breast Cancer Research and Treatment;2024-07-05

2. A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105);2024-04-29

3. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab;Pathology - Research and Practice;2023-12

4. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies;International Journal of Biological Macromolecules;2021-08

5. Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment;Journal of Cancer Metastasis and Treatment;2020-11-30